AfterRaise/Companies/Anodyne Nanotech

Anodyne Nanotech

Anodyne Nanotech is a clinical-stage biotechnology company which specializes in chronic care through transdermal delivery. From its funding announcement.

$13M Series ARaised 4 months agoBoston, USABiotech & PharmaUSA
Visit website →

In their own words

What Anodyne Nanotech says it is doing

Work here? Claim your company profile

Public signal Described in the funding announcement as "clinical-stage biotechnology company which specializes in chronic care through transdermal delivery". Source

ProductResearch and developmentManufacturing and scale

Public signal Read from the company's own description of what the funding supports.

Why now

Where Anodyne Nanotech is today

Anodyne Nanotech announced a Series A round of $13M on 24 June 2026, led by Velocity Partners VC and Evercurious VC.

Latest round
Series A
Amount
$13M
Announced
24 June 2026
Headquarters
Boston, USA
Sector
Biotech & Pharma
Investors
Also participating
Relativity Healthcare Partners
Relevant leadership
CEO Jake Lombardo

Momentum AfterRaise intelligence

AfterRaise Score

45
Steady growth
0 funding signals in the last 90 days
Funding recency
18/40
announced within the last 6 months
Round scale
12/25
round size relative to the market
Funding stage
15/20
Series A
Funding cadence
0/15
one funding event tracked this year
Arriving with the signals layer
  • Hiring momentum Open roles and hiring pace
  • Market expansion New offices and new countries
  • Leadership Executive appointments
  • Product activity Launches and releases

Since the raise

What has happened since

  • 24 June 2026
    $13M Series A
    Led by Velocity Partners VC and Evercurious VC.

Public signal The timeline currently holds funding events, because those are the signals AfterRaise observes today. Hiring, leadership, expansion and product events join it with the signals layer.

What may happen next

What this raise could create

AfterRaise intelligenceNot a statement of fact

What may happen next

  • Product launches and new tiers
  • Product leadership hiring
  • Research programme expansion
  • Scientific team growth

Opportunities this could create

  • Clinical operations
  • CMC and manufacturing
  • Quality systems
  • Scientific hiring
  • Licensing and BD partnerships

Based on the Biotech & Pharma sector, a Series A round and the priorities the company itself set out. Not a statement of fact.

Medium momentum4 connected signals
  • 24 June 2026$13M Series A announced
  • 24 June 2026Stated priority: product
  • 24 June 2026Stated priority: research and development
  • 24 June 2026Stated priority: manufacturing and scale

High momentum means several meaningful company changes have occurred in a short period. Signals here are funding events and the priorities the company stated; hiring, leadership and expansion detection join with the signals layer.

Open to

What Anodyne Nanotech is open to

Not yet specified

Anodyne Nanotech has not told AfterRaise which approaches it welcomes. Until it does, we do not assume. Offers to help are held and shown to the company, and the company decides whether to open a conversation.

Work here? Set your preferences

Opportunities

Ways to work with Anodyne Nanotech

No open opportunities listed

Jobs, projects, partnerships, advisory and supplier needs appear here once the company has claimed its page and published them, and any role we read from its own job board appears automatically.

Work here? Open the first one

Helpful contributors

People who have contributed here

Nobody yet

When someone offers help and the company says it was useful, they appear here. Reputation on AfterRaise is built from contributions the company confirmed, not from follower counts.

Do you work at Anodyne Nanotech?

Claim your company profile.

This page was created from publicly available information. A verified representative corrects the record, says what the company is building next and chooses which conversations it welcomes.

What we do not have yet: the roles and projects you have open. Claiming the page is how you fill those in.

Someone else requesting access does not give them ownership. Every representative is verified by a person before access is granted.

Maintaining your own company profile is free. A founder, CEO or authorised senior colleague can represent the company.

Also moving

Other Biotech & Pharma companies

See the sector